Stelexis Therapeutics, a NYC-based cancer therapeutics company, closed a $43m Series A financing.
Deerfield established Stelexis in 2017 together with scientific founders, Ulrich Steidl, Evripidis Gavathiotis, Amit Verma, and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Health, New York and Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.
Patrick Doyle serves as the founding CEO, and Keren Paz is the CSO of Stelexis.
The company intends to use the funds to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.
Stelexis is a cancer therapeutics company, utilizing its proprietary platform to selectively target pre-cancerous stem cells to discover and develop transformative therapies. Its proprietary drug discovery platform identifies the earliest definable pre-cancerous stem and progenitor cells that lead to the formation of human primary and recurrent tumors for therapeutic intervention and relapse prevention. The company’s mission is to develop novel cancer drugs that selectively target these critical pre-cancerous events related to both hematopoietic and solid malignancies.